<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156563">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02129192</url>
  </required_header>
  <id_info>
    <org_study_id>1348.4</org_study_id>
    <nct_id>NCT02129192</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use</brief_title>
  <official_title>Bioequivalence of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet Compared to Concomitant Administration of Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet and Amlodipine 5 mg Capsule in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study), With Influence of Food on the Bioavailability of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be performed as an open-label, randomised, single-dose, two-sequence,
      four-period replicated crossover design for the assessment of bioequivalence. A total of 72
      healthy male subjects will be randomised to 2 groups. The subjects are administrated either
      T80/A5/H12.5 mg FDC tablet once or T80/H12.5 mg FDC tablet and A5 mg capsule once in each
      period. In addition, the study will be assessed the effect of food on bioavailability and
      pharmacokinetics (PK) for T80/A5/H12.5 mg FDC tablet. The length of admission will be 7days
      in each period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum measured concentration (Cmax) of the analyte in plasma</measure>
    <time_frame>up to 144 hours from drug administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC 0-tz) of the analyte in plasma over the time interval from 0 to the last quantifiable plasma concentration</measure>
    <time_frame>up to 144hours from drug administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC 0-infinity) of the analyte in plasma over the time interval from 0 to extrapolated infinity</measure>
    <time_frame>up to 144hours from drug administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>T80/A5/H12.5 mg FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T80/H12.5 FDC + A5 mono</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet and Amlodipine 5 mg capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5mg capsule</intervention_name>
    <description>Amlodipine 5mg capsule</description>
    <arm_group_label>T80/H12.5 FDC + A5 mono</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T80/H12.5 mg FDC tablet</intervention_name>
    <description>Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet</description>
    <arm_group_label>T80/H12.5 FDC + A5 mono</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T80/A5/H12.5 mg FDC tablet</intervention_name>
    <description>Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet</description>
    <arm_group_label>T80/A5/H12.5 mg FDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy male subjects age &gt;=20 and &lt;=35 years; body weight: &gt;=50 kg and &lt;=80 kg; body
             mass index: &gt;=18.0 and &lt;=25.0 kg/m2

          -  Without any clinically significant findings and complications on the basis of a
             complete medical history, including the physical examination, vital signs (blood
             pressure (BP), pulse rate (PR), body temperature)

          -  Signed and dated written informed consent prior to admission to the trial in
             accordance with the Good Clinical Practice (GCP) and the local legislation

        Exclusion criteria:

        - Any finding of the medical examination (including BP, PR and ECGs) deviating from normal
        and of clinical relevance
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1348.4.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Hachioji</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>April 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Benzoates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
